<DOC>
	<DOCNO>NCT00410202</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness entecavir plus adefovir combination therapy versus entecavir monotherapy therapy adefovir plus lamivudine</brief_summary>
	<brief_title>Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy v Therapy With Adefovir Plus Lamivudine Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Evidence lamivudine ( LVD ) resistance Subjects must history previous LVD treatment screening , must evidence least 1 LVD resistance substitution ( valine , isoleucine , serine ) reverse transcriptase codon 204 ( M204V/I/S ) Nucleoside nucleotidenaive , except LVD , chronic hepatitis B ( HBV ) infection Compensated liver function must meet ALL follow criterion : International normalization ratio ( INR ) ≤ 1.5 ; Serum albumin ≥ 3 g/dL ( ≥ 30 g/L ) ; Serum total bilirubin ≤ 2.5 mg/dL ( ≤ 42.75 μmol/L ) HBV DNA &gt; 1.72 x 10*4* IU/mL ( approximately 10*5* copies/mL ) Documentation hepatitis B e antigen ( HBeAg ) positive hepatitis B e antibody ( HBeAb ) negative status screen alanine aminotransferase ( ALT ) ≤ 10 * upper limit normal ( ULN ) screen Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study ( 6 week last dose investigational product ) manner risk pregnancy minimize WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal . Post menopausal define : Women use oral contraceptive , hormonal contraceptive ( vaginal product , skin patch , implant injectable product ) , mechanical product intrauterine device barrier method ( diaphragm , condom , spermicide ) prevent pregnancy , practice abstinence partner sterile ( e.g. , vasectomy ) , consider child bear potential WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit human chorionic gonadotropin ) within 72 hour prior start investigational product Evidence decompensated cirrhosis Coinfection human immunodeficiency virus , hepatitis C virus , hepatitis D virus Women pregnant breastfeed Sexually active fertile men use effective birth control partner WOCBP Laboratory value protocolspecified range</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>